Longevity
The Accidental Gerotherapeutic
METHOD IN BRIEF Outcome evidence in this article is taken from published trial results and approved label language only. No efficacy or outcome claim is s...
August 30, 2026 | Analysis
The Biological Age Business
On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...
August 27, 2026 | Analysis
Asia-Pacific’s Geroscience Paradox: Plenty of Ageing Research, Just Five Clinical Assets
It is not a settled matter. It is a claim that has been made continuously for four years without anyone publishing the test they applied. So we wrote a tes...
August 13, 2026 | Analysis
The Sarcopenia Definition Race: The Endpoint Is the Asset
In a category with no approvable indication anywhere in the world, whoever writes the endpoint definition controls who is eligible for a trial, what counts...
August 12, 2026 | Analysis
Reading the Register: What Japan's Provision Plans Actually Say
A register, not an approval list Start with the thing that is most often got wrong, including by people who should know better. The Act on the Safety of ...
August 10, 2026 | Analysis
Why Asia Pacific Must Rethink Chronic Care Before the Demographic Tipping Point
Asia Pacific’s ageing economies are entering a more demanding phase of healthcare planning. As populations live longer, the challenge for healthcare ...
August 10, 2026 | Opinion | By Ambra Debernardi, Head of Employee Benefits and Corporate Relationships, APAC, Zurich Insurance
Aging Is Not an Indication. Asia-Pacific Found Three Ways Around It.
Feature | Longevity and geroscience | BioPharma APAC The closed front door Start with the fact that shapes everything else. There is no jurisdiction on...
August 07, 2026 | Analysis
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
